Investigational Drug Information for Palovarotene
✉ Email this page to a colleague
What is the drug development status for Palovarotene?
Palovarotene is an investigational drug.
There have been 10 clinical trials for Palovarotene.
The most recent clinical trial was a Phase 2 trial, which was initiated on November 15th 2021.
The most common disease conditions in clinical trials are Myositis Ossificans, Exostoses, Multiple Hereditary, and Keratoconjunctivitis Sicca. The leading clinical trial sponsors are Clementia Pharmaceuticals Inc., Ipsen, and [disabled in preview].
There are twenty-three US patents protecting this investigational drug and two hundred and thirty-five international patents.
Summary for Palovarotene
| US Patents | 23 |
| International Patents | 235 |
| US Patent Applications | 81 |
| WIPO Patent Applications | 53 |
| Japanese Patent Applications | 16 |
| Clinical Trial Progress | Phase 2 (2021-11-15) |
| Vendors | 35 |
Recent Clinical Trials for Palovarotene
| Title | Sponsor | Phase |
|---|---|---|
| A Rollover Study to Further Evaluate the Safety and Efficacy of Palovarotene Capsules in Male and Female Participants Aged ≥14 Years With Fibrodysplasia Ossificans Progressiva (FOP) Who Have Completed the Relevant Parent Studies. | Ipsen | Phase 3 |
| Study Evaluating the Effect of Food on the Pharmacokinetics of Palovarotene and the Effect of Palovarotene on the Pharmacokinetics of the CYP3A4 Substrate Midazolam in Two Cohorts of Healthy Adult Subjects | Clementia Pharmaceuticals Inc. | Phase 1 |
| Study to Assess Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of Palovarotene Ophthalmic Solution in Healthy Adult Subjects | Ipsen | Phase 1 |
Clinical Trial Summary for Palovarotene
Top disease conditions for Palovarotene
Top clinical trial sponsors for Palovarotene
US Patents for Palovarotene
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Palovarotene | See Plans and Pricing | Therapeutic agent for keratoconjunctive disorders | YAMAGUCHI UNIVERSITY (Yamaguchi, JP) | See Plans and Pricing |
| Palovarotene | See Plans and Pricing | Controlled release dosage form | TRIASTEK, INC. (Nanjing, CN) | See Plans and Pricing |
| Palovarotene | See Plans and Pricing | Inhibitors of activin receptor-like kinase | BLUEPRINT MEDICINES CORPORATION (Cambridge, MA) | See Plans and Pricing |
| Palovarotene | See Plans and Pricing | Oral drug dosage forms having desired drug release profiles and uses thereof | Triastek, Inc. (Nanjing, CN) | See Plans and Pricing |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Palovarotene
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Palovarotene | Australia | AU2013342882 | 2032-11-08 | See Plans and Pricing |
| Palovarotene | Australia | AU2018217197 | 2032-11-08 | See Plans and Pricing |
| Palovarotene | Brazil | BR112015010428 | 2032-11-08 | See Plans and Pricing |
| Palovarotene | Canada | CA2890424 | 2032-11-08 | See Plans and Pricing |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
